ELISpot and FluoroSpot Assay Market Size and Share Analysis by Based on Product Type, Application, End User - Global Industry Demand Forecast to 2030
세계의 ELISpot 및 FluoroSpot 어세이(ELISpot and FluoroSpot Assay) 시장 규모는 2023년에 2억 8,950만 달러로, 2024년부터 2030년에 걸쳐 CAGR 7.9%로 확대되어 2030년에는 4억 9,080만 달러에 달할 것으로 예상됩니다.
분석 키트가 최대 점유율을 차지
감염과 만성 질환의 이환율이 증가하고 이에 따른 분석 키트의 개발로 분석 키트는 지난 10년 말까지 시장을 선도할 것으로 보입니다.
ELISpot 분석은 인터페론, 염증성 매개체, 인터루킨과 같은 면역 매개체에 대한 백신 효율을 조사하는데 사용됩니다. 또한 이 분석의 주요 이점은 비용 효과적이고 결과가 빠르게 표시된다는 것입니다.
병원 및 클리닉이 주요 최종 사용자
2023년 시장 점유율은 병원 및 클리닉이 60%로 가장 컸습니다. 이는 특히 신흥국에서 병원 및 진료소가 질병 진단을 위해 많은 환자들에게 선호되기 때문입니다.
북미가 시장 리더
북미는 2023년에는 55%의 점유율을 획득하여 지역별로 가장 큰 시장이 되었습니다. 미국 인구조사국에 따르면 미국에는 65세 이상의 성인이 약 5,600만명 있어, 이 나라의 총 인구의 약 16.9%를 차지하고 있습니다.
중국이 아시아 태평양 시장을 선도
아시아 태평양에서는 중국이 가장 빠르게 성장하는 시장입니다. 여기에는 암과 기타 만성질환의 유행, 연구개발활동의 중점화, 환자수 증가, 의료지출의 급증이 크게 관련되어 있습니다.
세계의 ELISpot 및 FluoroSpot 어세이(ELISpot and FluoroSpot Assay) 시장을 분석했으며, 시장의 기본 구조/최신 상황/주요 촉진 및 억제 요인/전 세계 및 지역별 및 주요 국가 시장 규모 동향 전망(금액 기준, 2017-2030년)/제품별·용도별·최종 사용자별 상세 동향/현재 시장 경쟁 구도/주요 기업 프로파일 등 정보를 전해드립니다.
목차
제1장 조사 범위
제2장 조사 방법
제3장 주요 요약
제4장 시장 지표
제5장 산업 전망
- 시장 역학
- 동향
- 성장 촉진 요인
- 억제 요인/과제
- 성장 촉진 요인/억제 요인의 영향 분석
- COVID-19의 영향
- Porter's Five Forces 분석
제6장 시장
- 개요
- 시장 매출 : 제품별(2017-2030년)
- 시장 매출 : 용도별(2017-2030년)
- 시장 매출 : 최종 사용자별(2017-2030년)
- 시장 매출 : 지역별(2017-2030년)
제7장 북미 시장
- 개요
- 시장 매출 : 제품별(2017-2030년)
- 시장 매출 : 용도별(2017-2030년)
- 시장 매출 : 최종 사용자별(2017-2030년)
- 시장 매출 : 국가별(2017-2030년)
제8장 유럽 시장
제9장 아시아 태평양 시장
제10장 남미 시장
제11장 중동 및 아프리카(MEA) 시장
제12장 미국 시장
- 개요
- 시장 매출 : 제품별(2017-2030년)
- 시장 매출 : 용도별(2017-2030년)
- 시장 매출 : 최종 사용자별(2017-2030년)
제13장 캐나다 시장
제14장 독일 시장
제15장 프랑스 시장
제16장 영국 시장
제17장 이탈리아 시장
제18장 스페인 시장
제19장 일본 시장
제20장 중국 시장
제21장 인도 시장
제22장 호주 시장
제23장 한국 시장
제24장 브라질 시장
제25장 멕시코 시장
제26장 사우디아라비아 시장
제27장 남아프리카 시장
제28장 아랍에미리트(UAE) 시장
제29장 경쟁 구도
- 시장 진출기업 및 제공 제품 및 서비스 목록
- 주요 기업의 경쟁 벤치마킹
- 주요 기업의 제품 벤치마킹
- 최근의 전략 전개 상황
제30장 기업 프로파일
- Oxford Immunotec
- Cellular Technology Limited
- Mabtech AB
- Becton, Dickinson and Company
- Bio-Techne Corporation
제31장 부록
LYJ
The value of the ELISpot and FluoroSpot assay market was USD 289.5 million in 2023, and it will power at a compound annual growth rate of 7.9% during 2024-2030, to touch USD 490.8 million by 2030.
Market Drivers
Some driving factors of the industry are the growing occurrence of infectious and chronic diseases at a global level, particularly HIV, and the growing elderly population.
ELISpot and FluoroSpot are performed for several diseases, for instance, cancer, infectious diseases, and, autoimmune ailments. The ELISpot assay clearly spots the number of cytokine-secreting cell with high specialty and sensitivity.
These benefits make it an effective tool for measuring the degree of adaptive and innate immune responses.
As stated by the CDC's NCEZID, the infectious disease risk is increasing incessantly due to the change in climate all over the world.
Lyme disease, Valley fever, and West Nile disease are some infectious diseases, rising in prevalence and spreading to novel regions of the U.S. This is because of the warmer summers, milder winters, and fewer days with frost.
Assay Kits Hold Largest Share
Assay kits will lead the market by the end of this decade because of the growing incidence of infectious and chronic ailments, accompanied by the development in assay kits.
The ELISpot assay is used to examine the vaccine efficiency on immune mediators, for example, interferons, pro-inflammatory mediators, and interleukins. Additionally, the main benefit of this assay is that it is cost-effective and displays results quickly.
Hospitals and Clinics are the Major End Users
Hospitals and clinics were the leaders of the market, with a share of 60%, in 2023. This is because hospitals and clinics and preferred by most patients for disease diagnosis, particularly in emerging countries.
Furthermore, with continued efforts of the government, the count of such medical centers is on the rise, at a global level, which drives the demand for all sorts of therapeutic and diagnostic equipment at these places.
For addressing the huge demand for biopharmaceuticals, there is a growing emphasis on research and, related spending. The capability of biopharmaceuticals for treating ailments that were incurable before has brought about the release of these kinds of new medications in the market.
Therefore, the market under investigation will grow by the end of this decade.
North America is the Leader of the Market
North America was the regional leader of the market, with a 55% share, in 2023. As per the U.S. Census Bureau, approximately 56 million adults aged 65 or more are in the U.S. and make about 16.9% of the total population of the country.
Further, there will be over 73 million older adults by the time 2030 comes to an end, which means over 20% of people will be older. The total count of adults aged 65 and more will increase to 85.7 million by 2050 and will comprise 22% of the total population of the nation.
China Leads the Pack in the APAC Market
In the APAC region, China will be the fastest-growing market. This has a lot to do with the prevalence of cancer and other chronic ailments, increasing emphasis on research and development activities, rising patient populace, and surging healthcare spending.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by product type
- 1.4.2. Market size breakdown, by application
- 1.4.3. Market size breakdown, by end user
- 1.4.4. Market size breakdown, by region
- 1.4.5. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Product Type (2017-2030)
- 6.3. Market Revenue, by Application (2017-2030)
- 6.4. Market Revenue, by End User (2017-2030)
- 6.5. Market Revenue, by Region (2017-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Product Type (2017-2030)
- 7.3. Market Revenue, by Application (2017-2030)
- 7.4. Market Revenue, by End User (2017-2030)
- 7.5. Market Revenue, by Country (2017-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Product Type (2017-2030)
- 8.3. Market Revenue, by Application (2017-2030)
- 8.4. Market Revenue, by End User (2017-2030)
- 8.5. Market Revenue, by Country (2017-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Product Type (2017-2030)
- 9.3. Market Revenue, by Application (2017-2030)
- 9.4. Market Revenue, by End User (2017-2030)
- 9.5. Market Revenue, by Country (2017-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Product Type (2017-2030)
- 10.3. Market Revenue, by Application (2017-2030)
- 10.4. Market Revenue, by End User (2017-2030)
- 10.5. Market Revenue, by Country (2017-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Product Type (2017-2030)
- 11.3. Market Revenue, by Application (2017-2030)
- 11.4. Market Revenue, by End User (2017-2030)
- 11.5. Market Revenue, by Country (2017-2030)
Chapter 12. U.S. Market
- 12.1. Overview
- 12.2. Market Revenue, by Product Type (2017-2030)
- 12.3. Market Revenue, by Application (2017-2030)
- 12.4. Market Revenue, by End User (2017-2030)
Chapter 13. Canada Market
- 13.1. Overview
- 13.2. Market Revenue, by Product Type (2017-2030)
- 13.3. Market Revenue, by Application (2017-2030)
- 13.4. Market Revenue, by End User (2017-2030)
Chapter 14. Germany Market
- 14.1. Overview
- 14.2. Market Revenue, by Product Type (2017-2030)
- 14.3. Market Revenue, by Application (2017-2030)
- 14.4. Market Revenue, by End User (2017-2030)
Chapter 15. France Market
- 15.1. Overview
- 15.2. Market Revenue, by Product Type (2017-2030)
- 15.3. Market Revenue, by Application (2017-2030)
- 15.4. Market Revenue, by End User (2017-2030)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Market Revenue, by Product Type (2017-2030)
- 16.3. Market Revenue, by Application (2017-2030)
- 16.4. Market Revenue, by End User (2017-2030)
Chapter 17. Italy Market
- 17.1. Overview
- 17.2. Market Revenue, by Product Type (2017-2030)
- 17.3. Market Revenue, by Application (2017-2030)
- 17.4. Market Revenue, by End User (2017-2030)
Chapter 18. Spain Market
- 18.1. Overview
- 18.2. Market Revenue, by Product Type (2017-2030)
- 18.3. Market Revenue, by Application (2017-2030)
- 18.4. Market Revenue, by End User (2017-2030)
Chapter 19. Japan Market
- 19.1. Overview
- 19.2. Market Revenue, by Product Type (2017-2030)
- 19.3. Market Revenue, by Application (2017-2030)
- 19.4. Market Revenue, by End User (2017-2030)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Market Revenue, by Product Type (2017-2030)
- 20.3. Market Revenue, by Application (2017-2030)
- 20.4. Market Revenue, by End User (2017-2030)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Market Revenue, by Product Type (2017-2030)
- 21.3. Market Revenue, by Application (2017-2030)
- 21.4. Market Revenue, by End User (2017-2030)
Chapter 22. Australia Market
- 22.1. Overview
- 22.2. Market Revenue, by Product Type (2017-2030)
- 22.3. Market Revenue, by Application (2017-2030)
- 22.4. Market Revenue, by End User (2017-2030)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Market Revenue, by Product Type (2017-2030)
- 23.3. Market Revenue, by Application (2017-2030)
- 23.4. Market Revenue, by End User (2017-2030)
Chapter 24. Brazil Market
- 24.1. Overview
- 24.2. Market Revenue, by Product Type (2017-2030)
- 24.3. Market Revenue, by Application (2017-2030)
- 24.4. Market Revenue, by End User (2017-2030)
Chapter 25. Mexico Market
- 25.1. Overview
- 25.2. Market Revenue, by Product Type (2017-2030)
- 25.3. Market Revenue, by Application (2017-2030)
- 25.4. Market Revenue, by End User (2017-2030)
Chapter 26. Saudi Arabia Market
- 26.1. Overview
- 26.2. Market Revenue, by Product Type (2017-2030)
- 26.3. Market Revenue, by Application (2017-2030)
- 26.4. Market Revenue, by End User (2017-2030)
Chapter 27. South Africa Market
- 27.1. Overview
- 27.2. Market Revenue, by Product Type (2017-2030)
- 27.3. Market Revenue, by Application (2017-2030)
- 27.4. Market Revenue, by End User (2017-2030)
Chapter 28. U.A.E. Market
- 28.1. Overview
- 28.2. Market Revenue, by Product Type (2017-2030)
- 28.3. Market Revenue, by Application (2017-2030)
- 28.4. Market Revenue, by End User (2017-2030)
Chapter 29. Competitive Landscape
- 29.1. List of Market Players and their Offerings
- 29.2. Competitive Benchmarking of Key Players
- 29.3. Product Benchmarking of Key Players
- 29.4. Recent Strategic Developments
Chapter 30. Company Profiles
- 30.1. Oxford Immunotec
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
- 30.2. Cellular Technology Limited
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
- 30.3. Mabtech AB
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
- 30.4. Becton, Dickinson and Company
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
- 30.5. Bio-Techne Corporation
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
Chapter 31. Appendix
- 31.1. Abbreviations
- 31.2. Sources and References
- 31.3. Related Reports
